Skip to main content

Table 2 Summary characteristics of trials in the three registries

From: Trends in clinical trial registration in sub-Saharan Africa between 2010 and 2020: a cross-sectional review of three clinical trial registries

Description ISRCTN, N (%) CTG, N (%) PACTR, N (%)
Number of trials registered 507 2622 1501
Number of studies completed 386 (76.1) 1469 (56.0) -
Number of completed with results 224 (44.2) 243 (9.3) 40 (2.6)
Overall trial status
 Completed 386 (76.1) 1469 (56.0) -
 Ongoing/active 103 (20.3) 278 (10.6) -
 Not yet recruiting/pending 15 (3.0) 147 (5.6) 443 (29.5)
 Recruiting 49 (9.7) 429 (16.4) 324 (21.6)
 Stopped/terminated 2 (0.4) 65 (2.5) -
 Suspended 16 (3.2) 18 (0.7) -
 Withdrawn - 34 (1.3) -
 Other/unknown - 183 (7.0) -
Prospective/retrospective
 Prospectively registered 228 (45.0) - -
 Retrospectively registered 279 (55.0) - -
Study design
Allocation
  Randomised 450 (88.8) 2090 (79.7) 1319 (87.9)
  Non-randomised 50 (9.9) 224 (8.5) 175 (11.7)
  N/A 3 (0.6) 300 (11.4) 7 (0.5)
Intervention model
  Parallel assignment - 1919 (73.2) 1003 (66.8)
  Single group assignment - 414 (15.8) 49 (3.3)
  Cross-over assignment - 113 (4.3) 95 (6.3)
  Factorial assignment - 107 (4.1) 341 (22.9)
  Sequential assignment - 60 (2.3) -
  None (open label) - 7 (0.3) -
Masking
  None - 1577 (60.1) -
  Single - 348 (13.3) -
  Double - 224 (8.5) -
  Triple - 146 (5.6) -
  Quadruple - 312 (11.9) -
Phase
 Not applicable 149 (29.4) 1426 (54.4) 1301 (86.7)
 Not specified 10 (2.0)   
 Phase 0/early phase 1 - 11 (0.4) 43 (2.9)
 Phase I 4 (0.8) 169 (6.4) 43 (2.9)
 Phase I/II 3 (0.6) 109 (4.2)  
 Phase II 27 (5.3) 371 (14.1) 52 (3.5)
 Phase II/III 10 (2.0) 113 (4.3)  
 Phase III 57 (11.2) 423 (16.1) 60 (4.0)
 Phase III/IV 2 (0.4)   
Sponsor
 University 262 (51.7) 1618 (61.7) 496 (33.3)
 Industry/INGOa 16 (3.2) 288 (11.0) 27 (1.8)
 Research institution 105 (20.7) 1190 (45.4) 164 (10.9)
 Government 56 (11.0)   
 Charity 38 (7.5)   
 Hospital/clinic 16 (3.2) 437 (16.7) 94 (6.3)
 Private individuals    116 (7.7)
Sex
 Both 413 (81.5) 1961 (74.8) 1074 (71.6)
 Female 88 (17.4) 553 (21.1) 360 (24.0)
 Male 5 (1.0) 108 (4.1) 67 (4.5)
Target number of participants
 Min, maxa 0, 2,000,000 0, 650,000 0, 497,379
 Mean (SD)a 73,780 (338,098) 5298 (32,513) 1322 (15,010)
 Median (IQR)a 902 (2,004,000) 348 (1,001,233) 140 (60,400)
  1. INGO international non-governmental organisations
  2. aThis will not equal total completed trials because sponsor type was obtained by extracting the common theme from a free text, indicating the possibility of a double count